Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Clindamycin Phosphate

FDA-approved product (injectable, injection), marketed as Cleocin, Cleocin Phosphate, Cleocin Phosphate In Dextrose 5% In Plastic Container and 12 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Clindamycin Phosphate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Abdominal abscess
  • Abscess
  • Acne
  • Bacterial disease
  • Bacterial vaginosis
  • Empyema
  • Endometritis
  • Female reproductive system disease
  • Infection
  • Irritable bowel syndrome
  • Lung Abscess
  • Osteomyelitis
  • Parametritis
  • Peritonitis
  • Pneumonia
  • Pseudomembranous enterocolitis
  • and 3 more

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Antiinfectives for treatment of acne; Antibiotics; Lincosamides
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC D10AF01; WHO ATC J01FF01; WHO ATC G01AA10

Repurposing investigation

Clindamycin Phosphate is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA58.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli18.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae19.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis27.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Clindamycin Phosphate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Clindamycin Phosphate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Randomized, Multicenter, Open-label, Active-controlled Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Multiple Intravaginal Doses of GenSci142 in Patients With Bacterial Vaginosis (BV)

    NCT07663838 · start 2026-06-15

    Registered record
    Registry ID
    NCT07663838
    Conditions
    Randomized; Open-label; Safety; Tolerability; Pharmacokinetics; Bacterial Vaginosis
    Interventions
    GenSci142 capsule; clindamycin phosphate vaginal cream
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Not yet recruiting
    Start
    2026-06-15
    Completion
    2027-05-05
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRandomized; Open-label; Safety; Tolerability +2 more
    InterventionGenSci142 capsule; clindamycin phosphate vaginal cream
    PhasePhase 1
    Registry statusNot yet recruiting

  • Short Versus Standard of Care Antibiotic Duration for Children Hospitalized for CAP

    NCT06494072 · start 2024-08-22

    Registered record
    Registry ID
    NCT06494072
    Conditions
    Community Acquired Pneumonia in Children
    Interventions
    Ampicillin for Injection; Ceftriaxone for Injection; Amoxicillin; Ampicillin / Sulbactam Injection; Amoxicillin-clavulanate; Clindamycin; Cefprozil; Levofloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2024-08-22
    Completion
    2028-05
    Enrolment
    236

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCommunity Acquired Pneumonia in Children
    InterventionAmpicillin for Injection; Ceftriaxone for Injection; Amoxicillin; Ampicillin / Sulbactam Injection +4 more
    PhasePhase 4
    Registry statusRecruiting

  • Effect of Single vs Multiple Prophylactic Antibiotic Doses on PJI Following Primary THA in Patients With OA

    NCT05530551 · start 2022-09-01

    Registered record
    Registry ID
    NCT05530551
    Conditions
    Osteoarthritis, Hip; Total Hip Arthroplasty; Prosthetic-joint Infection
    Interventions
    Antibiotic dosage practice
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2022-09-01
    Completion
    2025-09-01
    Enrolment
    20,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOsteoarthritis, Hip; Total Hip Arthroplasty; Prosthetic-joint Infection
    InterventionAntibiotic dosage practice
    PhaseNot applicable
    Registry statusCompleted

  • NextGen - Clinical Implication of Next Generation Sequencing

    NCT05206500 · start 2022-05-17

    Registered record
    Registry ID
    NCT05206500
    Conditions
    Urinary Tract Infections
    Interventions
    Antibiotic; Next Gen
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2022-05-17
    Completion
    2028-12
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrinary Tract Infections
    InterventionAntibiotic; Next Gen
    PhasePhase 4
    Registry statusRecruiting

  • Staphylococcus Aureus Network Adaptive Platform Trial

    NCT05137119 · start 2022-02-16

    Registered record
    Registry ID
    NCT05137119
    Conditions
    Staphylococcus Aureus Bacteremia
    Interventions
    Cefazolin; Penicillin; Clindamycin; Vancomycin; Effectiveness of early switch to oral antibiotics; Whole body FDG PET/CT Imaging
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2022-02-16
    Completion
    2028-12-01
    Enrolment
    8,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStaphylococcus Aureus Bacteremia
    InterventionCefazolin; Penicillin; Clindamycin; Vancomycin +2 more
    PhasePhase 4
    Registry statusRecruiting

  • Dual vs. Single-Antibiotic Impregnated Cement in Hemiarthroplasty for Femoral Neck Fracture

    NCT05164081 · start 2022-01-01

    Registered record
    Registry ID
    NCT05164081
    Conditions
    Femoral Neck Fractures; Prosthetic Infection
    Interventions
    antibiotic loaded bone cement (gentamicin+clindamycin) COPAL G+C (Heraeus).; antibiotic loaded bone cement (gentamicin) Paladins R+G (Heraeus) or Refobacin (Biomet).
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2022-01-01
    Completion
    2027-01-31
    Enrolment
    7,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFemoral Neck Fractures; Prosthetic Infection
    Interventionantibiotic loaded bone cement (gentamicin+clindamycin) COPAL G+C (Heraeus).; antibiotic loaded bone cement (gentamicin) Paladins R+G (Heraeus) or Refobacin (Biomet).
    PhasePhase 3
    Registry statusActive not recruiting

  • Dexamethasone for Cerebral Toxoplasmosis

    NCT04341155 · start 2021-04-16

    Registered record
    Registry ID
    NCT04341155
    Conditions
    Toxoplasmosis, Cerebral
    Interventions
    Dexamethasone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2021-04-16
    Completion
    2025-07
    Enrolment
    138

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionToxoplasmosis, Cerebral
    InterventionDexamethasone; Placebo
    PhasePhase 2
    Registry statusUnknown

  • Best Treatment Choice for Osteonecrosis of the Jaw

    NCT04512638 · start 2021-01-01

    Registered record
    Registry ID
    NCT04512638
    Conditions
    Medication Related Osteonecrosis of the Jaw
    Interventions
    Antibiotics; Chlorhexidine mouthwash; Minimally invasive surgery with LPRF; Surgical resection
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2021-01-01
    Completion
    2026-01-01
    Enrolment
    125

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMedication Related Osteonecrosis of the Jaw
    InterventionAntibiotics; Chlorhexidine mouthwash; Minimally invasive surgery with LPRF; Surgical resection
    PhasePhase 4
    Registry statusUnknown

  • Efficacy and Safety Profile of Remimazolam-alfentanil Combination for ERCP Sedation

    NCT04658173 · start 2020-12-22

    Registered record
    Registry ID
    NCT04658173
    Conditions
    Anesthesia
    Interventions
    remimazolam-alfentanil combination; propofol-alfentanil combination
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2020-12-22
    Completion
    2023-10-01
    Enrolment
    1,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnesthesia
    Interventionremimazolam-alfentanil combination; propofol-alfentanil combination
    PhaseNot applicable
    Registry statusUnknown

  • Initial Management of MRONJ Stages I and II, a Clinical Trial With Detection of Salivary Biomarkers

    NCT04584840 · start 2020-11-01

    Registered record
    Registry ID
    NCT04584840
    Conditions
    Osteonecrosis of the Jaw, Bisphosphonate Induced; Osteonecrosis of the Jaw, Bisphosphonate Related
    Interventions
    Surgical treatment
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2020-11-01
    Completion
    2024-01-15
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOsteonecrosis of the Jaw, Bisphosphonate Induced; Osteonecrosis of the Jaw, Bisphosphonate Related
    InterventionSurgical treatment
    PhaseNot applicable
    Registry statusUnknown

  • Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris

    NCT04321070 · start 2019-09-09

    Registered record
    Registry ID
    NCT04321070
    Conditions
    Acne Vulgaris
    Interventions
    Clindamycin Phosphate; Clindamycin Phosphate RLD; Placebos
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2019-09-09
    Completion
    2020-03-06
    Enrolment
    550

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcne Vulgaris
    InterventionClindamycin Phosphate; Clindamycin Phosphate RLD; Placebos
    PhasePhase 1
    Registry statusCompleted

  • Interest of High-dose Gentamicin Cement Associated With Clindamycin in Changes of Hip and Knee Prostheses

    NCT06183606 · start 2019-06-14

    Registered record
    Registry ID
    NCT06183606
    Conditions
    Hip or Knee Replacement
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2019-06-14
    Completion
    2023-12
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHip or Knee Replacement
    InterventionNot recorded
    PhaseNot recorded
    Registry statusUnknown

  • Duration of IM Injection and Pain Intensity

    NCT05822336 · start 2019-03-01

    Registered record
    Registry ID
    NCT05822336
    Conditions
    Pain Measurement
    Interventions
    Duration of Intramuscular Injections
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2019-03-01
    Completion
    2021-05-01
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPain Measurement
    InterventionDuration of Intramuscular Injections
    PhaseNot applicable
    Registry statusCompleted

  • Mass Screening and Treatment for Reduction of Falciparum Malaria

    NCT04093765 · start 2018-11-01

    Registered record
    Registry ID
    NCT04093765
    Conditions
    Plasmodium Falciparum Malaria
    Interventions
    Ultrasensitive Rapid Diagnostic Test (URDT); Antimalarials
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2018-11-01
    Completion
    2020-12-31
    Enrolment
    5,542

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPlasmodium Falciparum Malaria
    InterventionUltrasensitive Rapid Diagnostic Test (URDT); Antimalarials
    PhaseNot applicable
    Registry statusCompleted

  • A Study to Evaluate the Efficacy and Safety of Adapalene-Clindamycin Combination Gel in the Treatment of Acne Vulgaris

    NCT03615768 · start 2018-08-14

    Registered record
    Registry ID
    NCT03615768
    Conditions
    Acne Vulgaris
    Interventions
    Adapalene-Clindamycin Combination Gel; Adapalene Gel; Clindamycin Gel
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-08-14
    Completion
    2020-04-07
    Enrolment
    1,617

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcne Vulgaris
    InterventionAdapalene-Clindamycin Combination Gel; Adapalene Gel; Clindamycin Gel
    PhasePhase 3
    Registry statusCompleted